Fresh From the Bench: Latest Federal Circuit Court Case
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASE OF THE WEEK
Arthrex, Inc. v. Smith & Nephew, Inc., Appeal No. 2018-2140 (Fed. Cir. May 27, 2022)
In a return to the Federal Circuit, this case again sets precedent concerning Patent Office Director review of Patent Trial and Appeal Board (PTAB) decisions. In a prior iteration of the appeal, the Supreme Court held that inter partes reviews (IPRs), created by the America Invents Act, were unconstitutional because the PTAB judges who decide them are not appointed pursuant to the Appointments Clause of the U.S. Constitution. The Supreme Court remedied this by judicially reforming the statute to allow the Director of the Patent Office to review IPR decisions, and remanding the case “to the Acting Director of the Patent Office for him to decide whether to rehear” the case. See our write-up of the Supreme Court’s decision here.
On remand, Arthrex requested “rehearing by the Director.” However, the Director office was vacant, as was the Deputy Director office. Arthrex’s rehearing petition was thus heard by the Commissioner for Patents, pursuant to a standing directive in the case of vacancies at the top of the Patent Office. The Commissioner denied rehearing. Arthrex appealed, questioning whether the Commissioner’s decision was sufficient under the Supreme Court’s prior decision and under the Federal Vacancies Reform Act and the Constitution’s Separation of Powers.
By Nika Aldrich
Edited by: Nika Aldrich and Scott D. Eads, Schwabe, Williamson & Wyatt
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…